Abstract
Since the concept of companion diagnostics was introduced in 1990s, personalized medicine has become more and more prominent. A well-established example of personalized medicine is the approval of the drug Herceptin in patients with breast cancer who tested positive for human epidermal growth factor receptor 2 (HER2). This is also one of the earliest examples of a co-development drug and companion diagnostic (hereafter CDx) model before there was a formal regulatory process in place. The device (or test) technology, cutoff points, and performance of a CDx can all vary, and thus different tests are likely to identify different populations for a given drug. These aspects are critical components to clinical trial design for CDx corresponding therapeutic product.
Drug companies like to have a predictable regulatory route of drug development when companion diagnostic is involved. It is also important for drug companies to understand specific sets of statistical and clinical trial design questions to be addressed. In this chapter, we will discuss statistical considerations pertaining to companion diagnostics. In the first section, we will provide the overview of personalized medicine from statistical perspective. The second section discusses statistical issues relative to CDx development such as primary endpoint and data analysis need to support CDx clinical validation. In the third section, we will discuss statistical considerations including cutoff/threshold determination for CDx, Phase II/III clinical trial study designs; CDx bridging studies, and pre-screening bias. In the last two sections, we will present conclusion and recommendations. We hope that the book chapter will provide a good reference for statisticians, clinicians, and researchers from industry for statistical issues pertaining to companion diagnostic device in personalized medicine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Simon, R.M., Genomic Clinical Trials and Predictive Medicine. 2013: Cambridge University Press.
LaThangue, N.B., and Kerr, D.J. (2011).Predictive biomarkers :a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8, 587–596.doi: https://doi.org/10.1038/nrclinonc.2011.121
The US Food and Drug Administration: In Vitro Companion Diagnostic Devices Guidance for Industry and Food and Drug Administration Staff 2014
Jakka S, Rossbach M. An economic perspective on personalized medicine. The HUGO J 2013; 7:1.
Davies B. M., Rikabi S., French A., Pinedo-Villanueva R., Morrey M. E., Wartolowska K., et al. (2014). Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: a pilot study. J. Tissue Eng
List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools) http://www.fda.gov/companiondiagnostics.
Li M (2015) Statistical consideration and challenges in bridging study of personalized medicine. J Biopharm Stat. 25(3):397–407. doi: https://doi.org/10.1080/10543406.2014.920340
CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition. CLSI document EP17-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
European Medicines Agency. Reflection paper on co-development of pharmacogenomic biomarkers and assays in the context of drug development. European Medicines Agency [online], http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/07/WC500094445.pdf (2010).
Moore, M. W., Babu, D. & Cotter, P. D. Challenges in the codevelopment of companion diagnostics. Per. Med. 9, 485–496 (2012).
Fridlyand J, Simon RM, Walrath JC, et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov. 2013;12(10):743–755. doi: https://doi.org/10.1038/nrd4101
Yip, V., Hawcutt, D., and Pirmohamed, M. (2015). Pharmacogenetic markers of drug efficacy and toxicity. Clin. Pharmacol. Ther. 98, 61–70.doi: https://doi.org/10.1002/cpt.135
Trusheim, M.R., Burgess, B., Hu, S. X., Long, T., Averbuch, S.D., Flynn, A.A., et al.(2011).Quantifying factors for the success of stratified medicine. Nat. Rev. Drug Discov. 10, 817–833. doi:https://doi.org/10.1038/nrd3557
Alosh, M. and M.F. Huque, A flexible strategy for testing subgroups and overall population. Statistics in Medicine, 2009. 28(1): p. 3–23.
Wang, S.-J., R.T. O’Neill, and H.M.J. Hung, Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics, 2007. 6(3): p. 227–244.
Kim, E.S., et al., The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery, 2011.
Liu, A., et al., A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations. Clinical trials (London, England), 2010. 7(5): p. 537–545.
Rosenblum, M. and M.J. van der Laan, Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment. Biometrika, 2011. 98(4): p. 845–860.
Simon, N. and R. Simon, Adaptive enrichment designs for clinical trials. Biostatistics (Oxford, England), 2013. 14(4): p. 613–625
Tang R., Biomarker-Defined Subgroup Selection Adaptive Design for Phase III Confirmatory Trial with Time-to-Event Data: Comparing Group Sequential and Various Adaptive Enrichment Designs 2017 Statistics in Biosciences DOI: https://doi.org/10.1007/s12561-017-9198-8
Zhiwei Zhang, Meijuan Li, Min Lin, Guoxing Soon, Tom Greene, Changyu Shen, Subgroup selection in adaptive signature designs of confirmatory clinical trials. Royal Statistical Society- Applied Statistics, 2017, 66:345–361
Buyse, M.; Michiels, S.; Sargent, D.J.; Grothey, A.; Matheson, A.; de Gramont, A. Integrating biomarkers in clinical trials. Expert Rev. Mol. Diagn. 2011, 11(2), 171–182.
Freidlin, B.; McShane, L.M.; Korn, E.L. Randomized Clinical Trials With Biomarkers: Design Issues. J. Natl. Cancer Inst. 2010, 102:152–160.
FDA Guidance Design Considerations for Pivotal Clinical Investigations for Medical Devices - Guidance for Industry, Clinical Investigators, Institutional Review Boards and Food and Drug Administration Staff 2013
Li, M., Pennello, G., Wu, J., et al. Personalized Medicine. Encyclopedia of Biopharmaceutical Statistics, 2016.
Acknowledgements
The authors gratefully thank Drs. Thomas Gross, Tinghui Yu, Jincao Wu, and Ram Tiwari from Center for Devices and Radiological Health, U.S. Food and Drug Administration.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Li, M., Tang, R. (2019). Statistical Considerations in the Development of Companion Diagnostic Device. In: Fang, L., Su, C. (eds) Statistical Methods in Biomarker and Early Clinical Development. Springer, Cham. https://doi.org/10.1007/978-3-030-31503-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-31503-0_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-31502-3
Online ISBN: 978-3-030-31503-0
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)